Evidence map›Paper›PMID 33116268›Full record

ArticleScientific reports2020

Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies.

Robert Pon, Anne Marcil, Wangxue Chen, Christine Gadoury, Dean Williams, Kenneth Chan, Hongyan Zhou, Amalia Ponce, Eric Paquet, Komal Gurnani and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Robert PonHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Anne MarcilHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Wangxue ChenHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Christine GadouryHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Dean WilliamsHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Kenneth ChanHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Hongyan ZhouHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Amalia PonceHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Eric PaquetDigital Technology Research Center, National Research Council of Canada, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.
Komal GurnaniHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Anindita ChattopadhyayHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada.
Wei ZouHuman Health Therapeutics Research Center, National Research Council of Canada, 100 Sussex Drive, Ottawa, ON, K1A 0R6, Canada. wei.zou@nrc-cnrc.gc.ca.
National Research Council Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycosylation of hydrophobic peptides at one terminus effectively increases their water-solubility, and conjugation through the opposing end to a carrier protein, renders them more immunogenic. Moreover, the glycosylation minimizes antibody responses to potentially deleterious, non-productive terminal neo-epitope regions of the peptides, and consequently shifts peptide immunogenicity towards the core amino acid residues. As proof of concept, glycopeptide-protein conjugates related to influenza hemagglutinin (HA), neuraminidase (NA), and the dimerization loop region of human epidermal growth factor receptor 2 (Her2), demonstrated a favorable production of core peptide specific antibodies as determined by ELISA studies. Furthermore, glycosylated Her2 peptide conjugate antisera were also shown to recognize full length Her2 protein by ELISA and at the cell surface through flow cytometry analysis. In contrast, unmasked peptide conjugates generated significant antibody populations that were specific to the terminal neo-epitope of the peptide immunogen that are notably absent in parental proteins. Antibodies generated in this manner to peptides in the dimerization loop of Her2 are also functional as demonstrated by the growth inhibition of Her2 expressing SKBR3 carcinoma cells. This method provides a technique to tailor-make epitope-specific antibodies that may facilitate vaccine, therapeutic and diagnostic antibody development.

Indexed as

AnimalsAntibodies, ViralAntibody FormationBiotinylationCarbohydratesDimerizationEnzyme-Linked Immunosorbent AssayEpitopesErb-b2 Receptor Tyrosine KinasesFemaleGlycopeptidesGlycosylationHemagglutinin Glycoproteins, Influenza VirusHumansImmune SystemInfluenza VaccinesAntibodies, ViralCarbohydratesEpitopesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGlycopeptidesHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNA protein, influenza A virusNeuraminidaseViral Proteins

Identifiers

PMID33116268
PMCPMC7595224
OpenAlexW3094988533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.